Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07673978
Active, not recruiting Phase 4

Effect of Ciprofol Injection on Postoperative Cognitive Function

NCT07673978 · tracked via the Priya Life Science China tracker
Sponsor
The Second Affiliated Hospital of Chongqing Medical University
Phase
Phase 4
Started
2026-06-01
Last updated
2026-06-29

Condition(s) studied

Postoperative Cognitive Dysfunction

Investigational drug(s) / intervention(s)

Ciprofol groupPropofol group

Ciprofol group: patients in the Ciprofol group will use ciprofol to complete the painless gastroscopy and colonoscopy treatment.

Propofol group: patients in the propofol group will use propofol to complete the painless gastroscopy and colonoscopy treatment.

Study summary

This study aims to explore the effect of ciprofol on the postoperative cognitive function of inpatients undergoing gastrointestinal endoscopy examination, to compare the anesthetic effects and differences in adverse reactions of propofol and ciprofol in gastrointestinal endoscopy , to compare the incidence of postoperative cognitive decline in patients undergoing gastrointestinal endoscopy examination between propofol and coprofol, and to optimize the anesthesia medication regimen for patients undergoing gastrointestinal endoscopy examination.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age: 18-65 years old, ASA grade I-Ⅲ, BMI index: 18.5-30 kg/m ² 2. Patients who plan to undergo gastroscopy or colonoscopy in our hospital 3. The preoperative assessment of the MOCA scale in patients scheduled for elective surgery indicated normal cognitive function 4. dextromanuality 5. Voluntarily participate in this study and sign the informed consent form Exclusion Criteria: 1. Pregnant or lactating women 2. Patients who have had cardiovascular and cerebrovascular accidents in the past 3. Patients with severe diseases of the cardiovascular system, respiratory system and liver and kidney system 4. Patients with obstructive sleep apnea syndrome 5. Patients with concurrent neurological or mental system diseases, or those with incomplete intellectual development 6. Patients allergic to ciprofol or propofol drugs 7. Patients with braking, visual/auditory impairments 8. Patients with psychotropic drug addiction or alcohol dependence 9. Patients who themselves or their attending physicians refused to participate in the study

Primary outcome measure(s)

  • The difference in the incidence of cognitive function decline between ciprofol and propofol in patients undergoing painless gastroscopy and colonoscopy treatment — From the time the patient was enrolled in the study to 24 hours after the treatment

Trial sites (1)

FacilityCityRegionStatus
The Second Affiliated Hospital Of Chongqing Medical University Chongqing Chongqing Municipality

More The Second Affiliated Hospital of Chongqing Medical University trials in China

Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS Recruiting
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B) Recruiting
The Effect of General Anesthesia with Remimazolam and Propofol on Rhythmic State and Cognitive Function Starting soon
Clinical Efficacy and Survival Prediction Analysis of Transjugular Intrahepatic Portosystemic Shunt in Patients With Liver Cirrhosis Active, not recruiting
Underdilated-stent Technique Improves Post-TIPS Encephalopathy Recruiting

Other trials for the same condition

Timing of Transcutaneous Acupoint Electrical Stimulation on Postoperative Recovery in Geriatric Patients with Gastrointestinal Tumor Starting soon
The Impact of Remimazolam Tosilate on Oxygenation and Postoperative Cognitive Function in Elderly Patients Undergoing Thoracoscopic Lobectomy Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07673978 on ClinicalTrials.gov ↗ ← All trials in China